Lv1
20 积分 2024-10-24 加入
Safety and efficacy of once-weekly efruxifermin versus placebo in metabolic dysfunction-associated steatohepatitis (HARMONY): 96-week results from a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial
20小时前
已完结
Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity
7天前
已完结
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
2个月前
已完结
Stem Cell–Derived, Fully Differentiated Islets for Type 1 Diabetes
2个月前
已完结
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
2个月前
已关闭
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: A randomized, double-blind, placebo-controlled study
2个月前
已完结
Safety and efficacy of GLP-1/FGF21 dual agonist HEC88473 in MASLD and T2DM: a randomized, double-blind, placebo-controlled study
3个月前
已完结
Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH
3个月前
已关闭
Once-Weekly Mazdutide in Chinese Adults with Obesity or Overweight
3个月前
已关闭
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA
3个月前
已完结
皖公网安备34019202002308
